O6-3 The significance of ultra-low EGFR T790M mutations on EGFR-TKI efficacy in patients with NSCLC -the WJOG13119L study

Takeshi Masuda,Hiroshi Watanabe,Kazuhiko Nakagawa,Satoshi Hara,Nobuyuki Yamamoto,Kazuo Nishikawa,Nobuhiro Kanaji,Ken Maeno,Kosuke Kashiwabara,Kazuhiro Yanagihara,Takaaki Tokito,Daisuke Hayakawa,Junichi Shimizu,Hidenori Koso,Hiroyasu Shoda,Shigeki Suzuki,Shinya Sakata,Tatsuro Okamoto,Hattori Noboru,S Miura

doi:10.1016/j.annonc.2022.05.028

O6-3 The significance of ultra-low EGFR T790M mutations on EGFR-TKI efficacy in patients with NSCLC -the WJOG13119L study

Takeshi Masuda, Hiroshi Watanabe + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.05.028

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Jul 1, 2022
License type: publisher-specific-oa

Affiliation: Hiroshima University Hospital

#Non-small Cell Lung Cancer #To Treatment Failure + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The significance of ultra-low pretreatment EGFR T790M mutations on EGFR-tyrosine kinase inhibitor (TKI) efficacy in patients with non-small cell lung cancer (NSCLC) remains uncertain. Therefore, we retrospectively investigated the association between ultra-low EGFR T790M mutations and time to treatment failure (TTF) in patients treated with 1st, 2nd or 3rd generation (1G, 2G, 3G) EGFR-TKI.

Full Text